Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

38.88
Delayed Data
As of Feb 24
 -0.68 / -1.72%
Today’s Change
17.02
Today|||52-Week Range
42.49
+34.81%
Year-to-Date
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
Feb 23 / Zacks.com - Paid Partner Content
Caution: Acadia Pharmaceuticals Is Overvalued
Feb 14 / MotleyFool.com - Paid Partner Content
Your Burning Biotech Questions Answered
Feb 20 / TheStreet.com - Paid Partner Content
A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Diseas...
Feb 11 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close39.56
Today’s open39.08
Day’s range38.16 - 39.43
Volume1,966,734
Average volume (3 months)2,561,253
Market cap$4.8B
Dividend yield--
Data as of 4:00pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-71.58%
Earnings growth (this year)-42.53%
Earnings growth (next 5 years)+15.31%
Revenue growth (last year)-49.17%
P/E ratioNM
Price/Sales58,810.80
Price/Book20.19

Competitors

 Today’s
change
Today’s
% change
OPKOPKO Health Inc-0.08-0.94%
PTHNPatheon NV-0.03-0.09%
TAROTaro Pharmaceutical ...-2.36-1.98%
GRFSGrifols SA+0.01+0.06%
Data as of 4:03pm ET, 02/24/2017

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)-$0.64
Annual revenue (last year)$61.0K
Annual profit (last year)-$164.4M
Net profit margin-269,578.69%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stephen R. Davis
Vice President-Technology Development &
Operations
James A. Nash
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs